Clinical trials: Non - Small Cell Lung Cancer NSCLC
Non-small Cell Lung Cancer (NSCLC)
Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC
This randomized controlled trial investigated the efficacy and safety of argon-helium cryoablation combined with PD-1 inhibitors compared to PD-1 inhibitors plus chemotherapy for treating non-small cell lung cancer (NSCLC).
- Trial name
- NCT07053215
- Testing
- Argon-Helium Cryoablation, Camrelizumab, Platinum-based doublet chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Hospital of Hebei Medical University
Non-small Cell Lung Cancer
Analysis of Soluble Mediators,Cytokines and FACs as Prognostic Factors in Advanced Non-squamous Lung Carcinoma
Recent studies have shown that the assessment of a set of cytokines and / or circulating angiogenic factors (FACs) could be used to identify prognostic factors predictive of efficacy and / or potential mechanisms of resistance to…
- Trial name
- NCT03156868
- Where
- 25 sites in Spain
- Volunteers
- 153 people
- Sponsor
- Spanish Lung Cancer Group
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
Leptomeningeal Metastasis
Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
The purpose of this study is to observe the clinical effect and safety of Recombinant Human Endostatin in non-small cell lung cancer with leptomeningeal metastasis
- Trial name
- NCT04356118
- Testing
- Recombinant Human Endostatin, intrathcal methotrexate, Targeted drugs for non-small cell lung cancer
- Volunteers
- 30 people
- Sponsor
- Hui Bu
NSCLC
Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC
Rationale: Immune checkpoint inhibitors have shown to improve the overall survival for patients with metastasized non-small cell lung carcinoma (NSCLC) but the optimal dosing and patient selection are still a matter of…
- Trial name
- DEDICATION-1 (NCT04909684)
- Testing
- Pembrolizumab
- Where
- Netherlands
- Volunteers
- 750 people
- Sponsor
- Radboud University Medical Center
Non-small Cell Lung Cancer (NSCLC)
Tumor-informed MRD for Non-small Cell Lung Cancer
The goal of this study is to evaluate the clinical utility of a personalized, WES-informed MRD detection approach in patients with early-stage non-small cell lung cancer, with a focus on its association with postoperative…
- Trial name
- NCT07596433
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-small Cell Lung Cancer
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
To determine whether dose escalation can provide a better survival to patients who failed with icotinib at routine dose.
- Trial name
- NCT01465243
- Testing
- Icotinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Radiotherapy, Non Small Cell Lung Cancer
Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC
The hypothesis for this study is that addition of a moderate dose of radiotherapy to the primary tumor and mediastinal nodes after three months of medical treatment could reduce the tumor burden, partly as an abscopal effect, and…
- Conditions
- Radiotherapy, Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Quality of Life
- Trial name
- MARS (NCT04530708)
- Testing
- Thoracic radiotherapy
- Where
- 3 sites in Sweden
- Volunteers
- 162 people
- Sponsor
- Swedish Lung Cancer Study Group
Lung Cancer
Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed. This may be effective against non-small cell lung cancer.
- Trial name
- NCT00754910
- Testing
- porfimer sodium, bronchoscopy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lung Cancer, Nonsmall Cell, Lung Cancer
Palliative Thoracic ImmunoRT
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada.
- Trial name
- NCT03705806
- Testing
- Radiation combined with immunotherapy
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Resectable Non-small Cell Lung Cancer
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
- Trial name
- NCT05247684
- Testing
- AK112, Carboplatin, Cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
This randomized pilot phase II trial studies the effect of pembrolizumab with or without carboplatin and paclitaxel on immune response in patients with non-small cell lung cancer that has come back or stage IIIB-IV.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02581943
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Wake Forest University Health Sciences
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful.
- Trial name
- NCT04886804
- Testing
- zongertinib
- Where
- 85 sites in United States, Australia and 16 more
- Volunteers
- 554 people
- Sponsor
- Boehringer Ingelheim
Melanoma, Non Small Cell Lung Cancer
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma
- Trial name
- NCT05366478
- Testing
- Autologous tumor infiltrating lymphocytes (TILs)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Non-small Cell Lung Cancer
Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody
to evaluate the prognosis of non-small cell lung carcinoma patients under CIK cellular treatment with PD-1 blocking on top of the standard therapy
- Trial name
- NCT03282435
- Testing
- CIK cells with PD-1 blocking, standard lung cancer treament, CIK cells without PD-1 blocking
- Volunteers
- 30 people
- Sponsor
- Dalian University
Lung Cancer
ALK Rearrangements in Lung Adenocarcinoma: Epidemiology in Latin America (CLICaP)
Evaluation of the frequency and clinical characteristics of ALK rearrangements in Latin-American countries. Latin American countries are heterogeneous in terms of lung cancer incidence, ethnicity, and exposure to potential…
- Trial name
- NCT02502240
- Where
- Mexico
- Volunteers
- 7,000 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
EGFR-mutant Non-small Cell Lung Cancer, SBRT
Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy
This national multicenter, randomized controlled clinical trial evaluates the safety and efficacy of consolidative stereotactic radiotherapy in patients with advanced EGFR-mutant non-small cell lung cancer who have oligo-residual…
- Conditions
- EGFR-mutant Non-small Cell Lung Cancer, SBRT, NSCLC (Advanced Non-small Cell Lung Cancer)
- Trial name
- NCT07822984
- Testing
- Third-generation EGFR tyrosine kinase inhibitor, Platinum plus pemetrexed chemotherapy, Pemetrexed maintenance therapy
- Volunteers
- 374 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer Stage III
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer
Concurrent chemoradiotherapy without disease progression followed by consolidation durvalumab is standard of care for unresectable, stage III non-small-cell lung cancer (NSCLC) (the 'PACIFIC regimen').
- Trial name
- NCT05557552
- Testing
- standar thoracic RT dose, decreased thoracic RT dose
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Ruijin Hospital
Non Small Cell Lung Cancer
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
This is a pilot single institution study of DRibble vaccination + GM-CSF in patients with stage IIIB or IV NSCLC who have undergone 0-1 chemotherapy regimens for metastatic disease.
- Trial name
- DRibble (NCT00850785)
- Testing
- DRibble vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services